The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Personalized risk stratification for patients with early prostate cancer (PRONTO): A Canadian team biomarker project.
 
David Monty Berman
No Relationships to Disclose
 
Robert Lesurf
No Relationships to Disclose
 
Anna YW Lee
No Relationships to Disclose
 
Palak Patel
No Relationships to Disclose
 
Tamara Jamaspishvili
No Relationships to Disclose
 
Walead Ebrahimizadeh
No Relationships to Disclose
 
John Okello
No Relationships to Disclose
 
Shaghayegh Rouzbeh
No Relationships to Disclose
 
Nadia Boufaied
No Relationships to Disclose
 
Laura A Lee
No Relationships to Disclose
 
Simone Chevalier
No Relationships to Disclose
 
Fadi Brimo
No Relationships to Disclose
 
Vasundara Venkateswaran
No Relationships to Disclose
 
Paul C Park
No Relationships to Disclose
 
Ralph Buttyan
No Relationships to Disclose
 
Axel A Thomson
No Relationships to Disclose
 
Jacques Lapointe
No Relationships to Disclose
 
Paul Christopher Boutros
Patents, Royalties, Other Intellectual Property - Holds patents on multiple biomarkers
 
John Bartlett
Honoraria - Oncology Education
Consulting or Advisory Role - BioNTech; bioTheranostics; Insight Genetics; True North Therapeutics
Research Funding - Genoptix; MammaPrint; NanoString Technologies; Stratifyer GmbH
Patents, Royalties, Other Intellectual Property - John Bartlett currently has 7 pending patents: 1. Methods and Devices for Predicting Anthracycline Treatment PCT/CA2015/050660, 2. Method and Apparatus for Predicting Risk in Breast Cancer US62/085,416, 3. Methods and Devices for Predicting Anthracycline (Inst)